Toronto, Ontario – TheNewswire - November 09, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is thrilled to announce it will be showcasing its AI-powered heart-imaging technology at the British Congenital Cardiac Association (BCCA) Annual Conference this year in Bristol, UK from Nov. 13th  to Nov. 14th .

As a Gold Level Sponsor, Ventripoint will have a designated booth for in-person demonstrations that will allow attendees to observe the VMS+ system in real-time, using AI to obtain MRI-equivalent cardiac metrics from ultrasound images.

“Ventripoint is looking forward to the exchange of ideas and demonstrating our diagnostic technology to other professionals in the echocardiography and cardiac field”, said Alvira Macanovic, Ventripoint’s President and CEO. “Our goal is to continue expanding Ventripoint’s adoption in hospitals and clinics around the world.”

The BCCA supports and represents medical practitioners in the practice or research of congenital heart disease. The BCCA attracts over 300 delegates worldwide, including cardiologists and sonographers focused exclusively on congenital heart defects in children and adults.

Ventripoint will also be joined by its UK representatives from Cardiologic, who specialize in medical devices in the cardiology field. This will give attendees the opportunity to connect with Cardiologic, which has extensive experience working with cardiologists, cardiac surgeons, and technicians.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Jonathan Robinson

This email address is being protected from spambots. You need JavaScript enabled to view it.

416-669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.